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Safety of Perioperative Aprotinin Administration During Isolated
Coronary Artery Bypass Graft Surgery: Insights From the ART
(Arterial Revascularization Trial)
Umberto Benedetto, MD, PhD; Douglas G. Altman, DSc; Stephen Gerry, MSc; Alastair Gray, PhD; Belinda Lees, BSc, PhD; Gianni D.
Angelini, MD; Marcus Flather, MD; David P. Taggart, PhD; on behalf of the ART (Arterial Revascularization Trial) Investigators*
Background-—There is still uncertainty about the safety of aprotinin for coronary artery bypass graft surgery. The ART (Arterial
Revascularization Trial) was designed to compare survival after bilateral versus single internal thoracic artery grafting. Many of the
ART patients (30%) received perioperative aprotinin. We investigated the association between perioperative aprotinin
administration and short-term (in-hospital) and long-term outcomes by performing a post hoc analysis of the ART.
Methods and Results-—Among patients enrolled in the ART (n=3102) from 2004 to 2007, we excluded those who did not undergo
surgery (n=18) and those with no information about use of perioperative aprotinin (n=9). Finally, 836 of 3076 patients (27%)
received aprotinin. Propensity matching was used to select 536 pairs for ﬁnal comparison. Aprotinin was also associated with an
increased risk of hospital mortality (9 [1.7%] versus 1 [0.2%]; odds ratio, 9.12; 95% conﬁdence interval [CI], 1.15–72.2; P=0.03),
intra-aortic balloon pump insertion (37 [6.9%] versus 17 [3.2%]; odds ratio, 2.26; 95% CI, 1.26–4.07; P=0.006), and acute kidney
injury (102 [19.0%] versus 76 [14.2%]; odds ratio, 1.42; 95% CI, 1.03–1.97; P=0.03). Aprotinin was not associated with a lower
incidence of transfusion (37 [6.9%] versus 28 [5.2%]; odds ratio, 1.34; 95% CI, 0.81–2.23; P=0.25) and reexploration (26 [4.9%]
versus 19 [3.5%]; hazard ratio, 1.39; 95% CI, 0.76–2.53; P=0.28). At 5 years, all-cause mortality was signiﬁcantly increased in the
aprotinin group (56 [10.6%] versus 38 [7.3%]; hazard ratio, 1.51; 95% CI, 1.0–2.28; P=0.045).
Conclusions-—In the present post hoc ART analysis, aprotinin was associated with a signiﬁcantly increased risk of early and late
mortality.
Clinical Trial Registration-—URL: http://www.isrctn.com. Unique identiﬁer: ISRCTN46552265. ( J Am Heart Assoc. 2018;7:
e007570. DOI: 10.1161/JAHA.117.007570.)
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B leeding remains a major complication after coronaryartery bypass graft (CABG) surgery and is associated
with poorer short- and long-term outcomes.1 Aprotinin is the
most studied antiﬁbrinolytic agent to limit blood loss in
cardiac surgery. However, concerns have been expressed
over its potential detrimental effect on short-term outcomes,
including renal dysfunction, graft occlusion, and stroke,2–5 as
well as late mortality.6 Aprotinin was taken off the market in
November 2007 because of safety concerns expressed in 4
studies in The New England Journal of Medicine.2–5 Ten years
later, aprotinin is being reintroduced, but without any new
clinical trials on safety. The regulatory authorities, including
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Health Canada and the European Medicines Agency, revisited
the previously available data, and after highlighting several
methodological limitations, they concluded that no ﬁrm
assumption could be made on mortality.7 Consequently,
aprotinin is currently being reestablished into clinical
practice in Europe and Canada for adult patients undergo-
ing isolated CABG who are at high risk of major blood
loss.8
The ART (Arterial Revascularization Trial) is designed to
compare 10-year survival after bilateral internal thoracic
artery versus single left internal thoracic artery grafting, and
an interim report at 5 years has not shown any clear
difference between the 2 groups.9 Approximately 30% of
patients enrolled in the ART received perioperative aprotinin.
We investigated the association between perioperative apro-
tinin administration and short- and long-term outcomes in
patients undergoing isolated CABG by conducting a post hoc
analysis on high-quality data from the ART.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of
reproducing the results or replicating the procedure. A post
hoc analysis of the ART was conducted. This research
adheres to the principles set forth in the Declaration of
Helsinki. In ART, aprotinin was the only antiﬁbrinolytic agent
administered perioperatively, and its use was based on
surgeon discretion/local policies. For the present analysis,
among patients enrolled in the ART (n=3102) from 2004 to
2007, we excluded those who did not undergo surgery
(n=18) and those with no information about use of
perioperative aprotinin (n=9). Perioperative aprotinin was
administered to 836 of 3076 patients (27.1%, aprotinin
group) included in the present analysis. The baseline
characteristics in the aprotinin and no aprotinin groups are
reported in Table S1. There was a large variation in aprotinin
use across different centers. Unadjusted hospital and long-
term outcomes in the 2 groups are reported in Tables S2
and S3.
Patient Involvement
Because the present study represents a post hoc observa-
tional analysis of the ART, there was no patient involvement.
Trial Design
The ART was approved by the institutional review board of all
participating centers, and informed consent was obtained
from each participant. The protocol for the ART has been
published.10 Brieﬂy, the ART is a 2-arm, randomized, multi-
center trial conducted in 28 hospitals in 7 countries, with
patients being randomized equally to single left internal
thoracic artery or bilateral internal thoracic artery grafts.
Eligible patients were those with multivessel coronary artery
disease undergoing CABG, including urgent patients. Only
emergency patients (refractory myocardial ischemia/cardio-
genic shock) and those requiring single grafts or redo CABG
were excluded.
Follow-Up
Questionnaires were sent to study participants by post every
year after surgery. No clinic visits were planned apart from the
routine clinical 6-week postoperative visit. Participants were
sent stamped addressed envelopes to improve the return
rates of postal questionnaires. Study coordinators contacted
participants by telephone to alert them to the questionnaire’s
arrival and to ask them about medications, adverse events,
and health services resource use.
Study Outcomes
Primary outcomes were hospital outcomes, which included
hospital death, myocardial infarction (MI), cerebrovascular
accident, need for repeated revascularization, postoperative
atrial ﬁbrillation, need for intra-aortic balloon pump insertion,
postoperative renal replacement therapy, acute kidney injury
(AKI), sternal wound infection, red blood cell transfusion, and
reexploration for bleeding. We also investigated the associ-
ation between perioperative aprotinin administration and
5-year mortality (including all-cause and cardiovascular mor-
tality), nonfatal MI, cerebrovascular accident, and repeated
revascularization.
Clinical Perspective
What Is New?
• Aprotinin is currently being reestablished into clinical
practice in Europe and Canada for adult patients undergoing
isolated coronary bypass surgery without any new clinical
trials on safety in this subgroup.
• The present analysis on a selected low-risk coronary bypass
surgery population supports the association between apro-
tinin administration and adverse hospital outcomes and
long-term survival.
What Are the Clinical Implications?
• On the basis of the present ﬁndings, a word of caution
should be exercised by local authorities on the liberal use of
aprotinin before further investigations will clarify the
potential risks related to its perioperative administration.
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Outcome Deﬁnitions
Death was classiﬁed into cardiovascular and noncardiovas-
cular, where possible, using autopsy reports and death
certiﬁcates. Congestive heart failure, arrhythmia or MI,
pulmonary embolus, and dissection were considered cardio-
vascular causes of death.
MI was diagnosed when 2 of the following 3 criteria were
present: (1) unequivocal ECG changes, (2) elevation of cardiac
enzyme(s) above twice the upper limit of normal or diagnostic
troponin increases, and (3) chest pain typical for acute MI,
which lasted >20 minutes. Cerebrovascular accident was
deﬁned as new neurological deﬁcit evidenced by clinical signs
of paresis, plegia, or new cognitive dysfunction, including any
mental status alteration lasting >24 hours and/or evidence on
computed tomographic or magnetic resonance imaging scan of
a recent brain infarct (<6 months). Repeated revascularization
was deﬁned as coronary bypass surgery or percutaneous
coronary intervention performed after the trial procedure. AKI
was deﬁned as a 0.3-mg/dL (≥26.5-mmol/L) creatinine
increase from baseline within 48 hours of surgery.11
Statistical Analysis
Multiple imputation (m=10) was used to address missing data
(Figure S1). The method of Rubin12 was used to combine
results from each of the imputed data sets (Amelia R
package). Because use of aprotinin was not based on
randomization, a propensity score (PS) was generated for
each patient from a multivariable logistic regression model on
the basis of baseline and intraoperative covariates as
independent variables, with aprotinin versus no aprotinin as
a binary dependent variable.13 Because a large variation in
aprotinin use was found among recruiting centers, individual
centers were also included into the PS model to adjust for
potential confounding related to different practice patterns.
Pairs of patients were derived using greedy 1:1 matching, with
a caliper of width of 0.2 SDs of the logit of the PS (MatchIt R
package). The quality of the match was assessed by graphical
visualization of PS distribution overlapping. Selected pretreat-
ment variables in PS–matched groups were compared using
the absolute standardized mean difference, with a value >0.10
taken to represent meaningful covariate imbalance. For
outcomes analysis, conditional logistic and Cox regression
models stratiﬁed for matched pairs with robust standard error
estimation were used to investigate the treatment effect on
short- and long-term outcomes, respectively. For competing
risks, a model for the subdistribution hazard of the cumulative
incidence function, proposed by Fine and Gray, was used14
(riskRegression R packages). The effect of aprotinin on long-
term mortality was also adjusted for medications prescribed
at discharge. P<0.05 was considered statistically signiﬁcant.
All statistical analysis was performed using R Statistical
Software (version 3.2.3; R Foundation for Statistical Comput-
ing, Vienna, Austria).
Results
PS Matching
Table S2 summarizes baseline characteristics of patients in
the original aprotinin and no aprotinin groups. Patients who
received aprotinin were more likely to be white, to be older,
and to have an advanced New York Heart Association
functional class. The use of aprotinin was also associated
with a higher rate of preoperative dual-antiplatelet adminis-
tration and use of cardiopulmonary bypass and saphenous
vein grafts. Patients who did not receive aprotinin were more
likely to be diabetic and to receive preoperative angiotensin-
converting enzyme inhibitors/receptor blockers. There were
also a few centers where the aprotinin administration rate
was extremely high (eg, Edinburgh Royal Inﬁrmary) and others
where the aprotinin administration rate was extremely low
(eg, Papworth Hospital and Austin Repatriation Medical
Centre). PS matching selected 536 matched pairs with similar
distribution of covariates and recruiting centers (all standard-
ized mean differences, <0.10), as shown in Table 1, and
comparable PS distribution (Figure 1).
Hospital Outcomes
Hospital outcomes in the matched sample are summarized in
Table 2. Hospital mortality was signiﬁcantly higher in the
aprotinin group (9 [1.7%] versus 1 [0.2%]; odds ratio [OR], 9.12;
95% conﬁdence interval [CI], 1.15–72.2; P=0.03). Aprotinin was
also associated with an increased risk of intra-aortic balloon
pump insertion (37 [6.9%] versus 17 [3.2%]; OR, 2.26; 95% CI,
1.26–4.07; P=0.006) and AKI (102 [19.0%] versus 76 [14.2%];
OR, 1.42; 95% CI, 1.03–1.97; P=0.03), although the increased
risk of renal replacement therapy in the aprotinin group did not
reach statistical signiﬁcance (25 [4.7%] versus 18 [3.4%]; OR,
1.41; 95% CI, 0.75–2.61; P=0.27). We also found a nonsignif-
icant trend toward increased risk of in-hospital repeated
revascularization in the aprotinin group (7 [1.3%] versus 2
[0.4%]; OR, 3.53; 95% CI, 0.73–17.1; P=0.1). Aprotinin was not
associated with a lower incidence of red blood cell transfusion
(37 [6.9%] versus 28 [5.2%]; OR, 1.34; 95% CI, 0.81–2.23;
P=0.25) or reexploration for bleeding (26 [4.9%] versus 19
[3.5%]; OR, 1.39; 95% CI, 0.76–2.53; P=0.28).
Five-Year Outcomes
Five-year outcomes are summarized in Table 3 and Fig-
ures 2 and 3. All-cause mortality was signiﬁcantly increased
in the aprotinin group (56 [10.6%] versus 38 [7.3%]; hazard
DOI: 10.1161/JAHA.117.007570 Journal of the American Heart Association 3
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Table 1. Baseline Characteristics of Patients in the Aprotinin and No Aprotinin Groups (Matched Sample)
Characteristics
Aprotinin
Group (n=536)
No Aprotinin
Group (n=536) SMD
Ethnicity 0.221
White 518 (96.6) 522 (97.4)
East Asian 3 (0.6) 0 (0.0)
South Asian 15 (2.8) 7 (1.3)
Afro-Caribbean 0 (0.0) 0 (0.0)
African 0 (0.0) 1 (0.2)
Other 0 (0.0) 6 (1.1)
Age, mean (SD), y 64.76 (9.15) 64.51 (8.56) 0.028
Female sex 81 (15.1) 71 (13.2) 0.054
BMI, mean (SD), kg/m2 28.10 (3.99) 28.24 (4.06) 0.034
Creatinine, mean (SD), mmol/L 96.28 (21.86) 95.84 (21.46) 0.020
NYHA class III/IV 103 (19.2) 98 (18.3) 0.024
Unstable angina 40 (7.5) 39 (7.3) 0.007
Diabetes mellitus 0.042
No history of diabetes mellitus 426 (79.5) 417 (77.8)
Insulin-dependent diabetes mellitus 23 (4.3) 26 (4.9)
Non–insulin-dependent diabetes mellitus 87 (16.2) 93 (17.4)
Smoking 0.100
Current smoker 91 (17.0) 87 (16.2)
Ex-smoker 294 (54.9) 319 (59.5)
Never smoked 151 (28.2) 130 (24.3)
COPD/asthma 37 (6.9) 34 (6.3) 0.023
PVD 35 (6.5) 41 (7.6) 0.044
CVA 19 (3.5) 19 (3.5) <0.001
MI 242 (45.1) 243 (45.3) 0.004
PCI 95 (17.7) 92 (17.2) 0.015
AF 10 (1.9) 9 (1.7) 0.014
LVEF 0.031
Good (≥50%) 423 (78.9) 418 (78.0)
Moderate (31%–49%) 104 (19.4) 110 (20.5)
Poor (≤30%) 9 (1.7) 8 (1.5)
Antiplatelet regimen 0.038
None 78 (14.6) 76 (14.2)
Aspirin only 313 (58.4) 321 (59.9)
Aspirin plus clopidogrel 124 (23.1) 121 (22.6)
Clopidogrel only 21 (3.9) 18 (3.4)
Antiplatelet within 3 d 116 (21.6) 117 (21.8) 0.005
Warfarin 10 (1.9) 10 (1.9) <0.001
b-Blockers 443 (82.6) 448 (83.6) 0.025
Statins 510 (95.1) 515 (96.1) 0.046
ACEI/ARB 358 (66.8) 346 (64.6) 0.047
Off-pump surgery 173 (32.3) 188 (35.1) 0.059
Continued
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ratio, 1.51; 95% CI, 1.0–2.28; P=0.045). We found an
excess of cardiovascular deaths, MIs, and repeated revas-
cularizations in the aprotinin group, although these differ-
ences did not reach statistical signiﬁcance. Medications at
discharge were comparable between the 2 groups (Table 4).
After controlling for medication at discharge, aprotinin
remained associated with a signiﬁcantly increased risk of
late death (hazard ratio, 1.54; 95% CI, 1.02–2.33; P=0.04).
Discussion
The present post hoc ART analysis found that, in patients
undergoing isolated CABG, aprotinin administration was
associated with a higher risk of in-hospital mortality, intra-
aortic balloon pump insertion, and AKI. We also found a
nonstatistically signiﬁcant increased risk of early reinter-
vention. At 5 years, perioperative aprotinin administration
was associated with signiﬁcantly higher mortality.
Table 1. Continued
Characteristics
Aprotinin
Group (n=536)
No Aprotinin
Group (n=536) SMD
Use of saphenous vein graft 439 (81.9) 448 (83.6) 0.044
No. of grafts, mean (SD) 3.17 (0.81) 3.20 (0.81) 0.030
Hospital 0.08
First Department of Cardiac Surgery 66 (12.3) 68 (12.7)
Second Department of Cardiac Surgery 46 (8.6) 44 (8.2)
Austin Repatriation Medical Centre 10 (1.9) 7 (1.3)
Bydgoszcz Szpital Uniwersytecki 0 (0.0) 0 (0.0)
Care Hospital 0 (0.0) 1 (0.2)
Castle Hill Hospital 39 (7.3) 34 (6.3)
Edinburgh Royal Infirmary 30 (5.6) 22 (4.1)
Escorts Heart Institute 0 (0.0) 0 (0.0)
Freeman Hospital 0 (0.0) 1 (0.2)
Glenfield Hospital 38 (7.1) 38 (7.1)
Harefield Hospital 28 (5.2) 25 (4.7)
Heart Institute of Pernambuco 0 (0.0) 2 (0.4)
John Paul Hospital 0 (0.0) 1 (0.2)
John Radcliffe Hospital 100 (18.7) 113 (21.1)
King’s College Hospital 0 (0.0) 0 (0.0)
Landesklinikum St Polten 6 (1.1) 2 (0.4)
Manchester Royal Infirmary 23 (4.3) 31 (5.8)
Medical University of Gdansk 3 (0.6) 3 (0.6)
Northern General Hospital 10 (1.9) 10 (1.9)
Ospedale Mauriziano 0 (0.0) 0 (0.0)
Papworth Hospital 2 (0.4) 4 (0.7)
Royal Brompton Hospital 25 (4.7) 24 (4.5)
Royal Sussex County Hospital 50 (9.3) 58 (10.8)
Rzeszow Szpital Wojewodzki 2 2 (0.4) 2 (0.4)
Silesian Centre for Heart Disease 0 (0.0) 0 (0.0)
St George’s Hospital 0 (0.0) 1 (0.2)
The Cardiothoracic Centre 0 (0.0) 0 (0.0)
University Hospital of Wales 58 (10.8) 45 (8.4)
Data are given as number (percentage) unless otherwise indicated. ACEI/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AF, atrial ﬁbrillation; BMI,
body mass index; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; and SMD, standardized mean difference.
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Aprotinin has been shown to effectively reduce blood loss
and the need for transfusion associated with heart surgery15;
currently, Health Canada and the European Medicines Agency
believe the accumulated evidence on the beneﬁts of aprotinin
outweighs its risks in isolated CABG surgery.7,8 In a prospec-
tive cohort study in 2006, Mangano and colleagues2 reported
that aprotinin was associated with an increased risk of renal
failure, MI, heart failure, stroke, encephalopathy, and mortality
(2.8% versus 1.3%; P=0.02). Consequently, in 2006, the Food
and Drug Administration listed renal dysfunction, along with
anaphylaxis, graft occlusion, and stroke, among the drug’s
safety concerns.16 However, the association between apro-
tinin and renal failure was disputed by Furnary and colleagues
in 2007, who suggested that this was a confounding variable
because renal impairment was also related to an increased
packed red cell transfusion in the setting of cardiac surgery.17
In 2007, Mangano and colleagues reanalyzed the 2006 data
and reported that aprotinin was independently predictive of
5-year mortality.6 A possible limitation of this analysis was
that the authors failed to report whether the surgery was on
or off pump, and this variable may have inﬂuenced not only
the choice of antiﬁbrinolytic agent but also clinical outcomes.
The Cardiovascular and Renal Drugs Advisory Committee of
the Food and Drug Administration reviewed the evidence from
these studies; the committee could not endorse the ﬁndings
after questions about the methods used, and because the
data had not been independently reviewed by the Food and
Drug Administration.18
Another source of concern about aprotinin’s safety was a
preliminary report in 2006, from the manufacturer’s own
database, that showed a higher risk of death and acute renal
failure in patients undergoing CABG who received aprotinin
compared with patients who had received other antiﬁb-
rinolytics.19 This study was limited by its inability to account
for the proportion of patients undergoing long-term dialysis
when assessing the need for postoperative dialysis. The BART
(Blood Conservation Using Antiﬁbrinolytics in a Randomized
Trial), published in 2008,5 was a blinded randomized
controlled trial comparing aprotinin, tranexamic acid, and
aminocaproic acid in patients undergoing high-risk cardiac
surgery. The trial was terminated early on the advice of the
Figure 1. Mirrored histogram showing propensity score (PS)
distribution in the 2 groups before (white) and after (red and blue)
matching.
Table 2. Hospital Outcomes in the Matched Sample
Outcomes
Aprotinin
Group (n=536)
No Aprotinin
Group (n=536) P Value OR (95% CI)
Mortality 9 (1.7) 1 (0.2) 0.03 9.12 (1.15–72.2)
MI 12 (2.2) 9 (1.7) 0.51 1.34 (0.56–3.21)
CVA 8 (1.5) 8 (1.5) 1.00 1 (0.37–2.68)
Repeated revascularization 7 (1.3) 2 (0.4) 0.11 3.53 (0.73–17.1)
POAF 143 (26.7) 169 (31.5) 0.09 0.79 (0.61–1.03)
IABP insertion 37 (6.9) 17 (3.2) 0.006 2.26 (1.26–4.07)
RRT 25 (4.7) 18 (3.4) 0.27 1.41 (0.75–2.61)
AKI 102 (19.0) 76 (14.2) 0.03 1.42 (1.03–1.97)
Sternal wound infection 25 (4.7) 19 (3.5) 0.35 1.33 (0.72–2.44)
RBC transfusion 37 (6.9) 28 (5.2) 0.25 1.34 (0.81–2.23)
Reexploration 26 (4.9) 19 (3.5) 0.28 1.39 (0.76–2.53)
Data are given as number (percentage) unless otherwise indicated. AKI indicates acute kidney injury; CI, conﬁdence interval; CVA, cerebrovascular accident; IABP, intra-aortic balloon
pump; MI, myocardial infarction; OR, odds radio; POAF, postoperative atrial ﬁbrillation; RBC, red blood cell; and RRT, renal replacement therapy.
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safety committee because of a nonsigniﬁcant increase in
mortality associated with aprotinin. Although the BART had
the beneﬁt of being a blinded randomized controlled trial,
several limitations were identiﬁed in its conduct, in particular
the unexplained exclusion of 137 patients from the analysis
after randomization.20 In view of conﬂicting ﬁndings reported,
further analyses based on high-quality data are warranted to
provide further evidence on the safety of perioperative
aprotinin administration.
The present post hoc ART analysis found that aprotinin
administration was signiﬁcantly associated with an increased
risk of hospital death, AKI, and need for intra-aortic balloon
pump insertion postoperatively, thus supporting previous
reports. We could not demonstrate a deﬁnitive association
between aprotinin administration and need for renal replace-
ment therapy, but this might be partially attributed to the
relatively low baseline renal risk of the present population. We
also found that aprotinin administration was associated with a
signiﬁcantly increased risk of late mortality. Although apro-
tinin administration was associated with reduced incidence of
red blood cell transfusion in the original sample (Table S2),
this association was no longer present after matching, which
also accounted for participating centers. This observation
suggests that in the ART, different transfusion policies, rather
than aprotinin itself, might have inﬂuenced red blood cell
transfusion exposure.
The main limitations of the present analyses are
obviously the nonrandomized comparison (despite the close
matching in the propensity-scored patients) and the few
outcome events, with consequently wide CIs. Despite PS
modeling, we cannot exclude a residual selection bias based
on unmeasured or unmeasurable characteristics. Another
limitation is that the exact dose of aprotinin administered
was not collected and, therefore, a dose-response associ-
ation cannot be excluded. However, a previous meta-
analysis did not ﬁnd any association between dose and
adverse events.21
In conclusion, we found that the use of aprotinin was
associated with an excess of early death and this also
translated into an increased cardiac-related mortality at
5 years. Aprotinin is currently offered to many patients
undergoing CABG, and the present analysis supports the
hypothesis that aprotinin use might be associated with an
increase in avoidable deaths. Therefore, a word of caution
should be exercised by local authorities on the liberal use of
aprotinin during isolated CABG before stronger evidence of its
safety proﬁle will be available.
Appendix
ART (Arterial Revascularization Trial) Contributors
C. Ratnatunga, S. Westaby, J. Cook, C. Wallis, S. Wos, M.
Jasinski, K. Widenka, A. Blach, R. Gocol, D. Hudziak, P. Zurek,
M. Deja, R. Bachowski, R. Mrozek, T. Kargul, W. Domarardzki,
J. Frackiewicz, V. Zamvar, D. Ezakadan, B. Buxton, S.
Seevanayagam, G. Matalanis, A. Rosalion, J. Negri, S. Moten,
Figure 2. Five-year cumulative incidence of all-cause mortality in
the matched groups.
Table 3. Five-Year Outcomes in the Matched Sample
Outcomes
Aprotinin
Group (n=536)
No Aprotinin
Group (n=536) P Value HR (95% CI)
Cardiovascular mortality 22 (4.1) 18 (3.4) 0.48 1.25 (0.67–2.33)
MI 18 (3.4) 15 (2.8) 0.58 1.21 (0.61–2.4)
CVA 12 (2.3) 19 (3.6) 0.23 0.64 (0.31–1.32)
Repeated revascularization 37 (7.0) 32 (6.1) 0.49 1.18 (0.74–1.9)
All-cause mortality 56 (10.6) 38 (7.3) 0.045 1.51 (1.0–2.28)
Data are given as number (percentage) unless otherwise indicated. CI indicates conﬁdence interval; CVA, cerebrovascular accident; HR, hazard ratio; and MI, myocardial infarction.
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Figure 3. Five-year cumulative incidence of cardiovascular (CV) death, myocardial infarction (MI),
cerebrovascular accident (CVA), and repeated revascularization in the matched groups.
Table 4. Medication at Discharge in the Matched Sample
Medications
Aprotinin
Group (n=536)
No Aprotinin
Group (n=536) P Value
b-Blocker 462 (86.2) 450 (84.0) 0.34
Statins 509 (95.0) 514 (95.9) 0.55
ACEI/ARB 307 (57.3) 296 (55.2) 0.53
Antiplatelet regimen 0.67
None 8 (1.5) 11 (2.1)
Aspirin only 416 (77.6) 417 (77.8)
Aspirin plus clopidogrel 92 (17.2) 94 (17.5)
Clopidogrel only 20 (3.7) 14 (2.6)
Warfarin 18 (3.4) 23 (4.3) 0.52
Data are given as number (percentage) unless otherwise indicated. ACEI/ARB indicates
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
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Supplemental Material 
Table S1. Baseline characteristics of patients in the aprotinin and no-aprotinin groups in the 
original sample. 
 Aprotinin No Aprotinin SMD 
n  836 2240  
Ethnicity (\%)    0.354 
    Caucasian 813 (97.2) 2012 (89.8)  
    East Asian 3 ( 0.4) 3 ( 0.1)  
    South Asian 20 ( 2.4) 129 ( 5.8)  
   Afro-Carribean 0 ( 0.0) 2 ( 0.1)  
   African  0 ( 0.0) 5 ( 0.2)  
   Other 0 ( 0.0) 89 ( 4.0)  
Age (years), mean (sd)) 64.84 (8.95) 63.17 (8.89) 0.187 
Female n(%) 125 (15.0) 314 (14.0) 0.027 
BMI (mean (sd))  28.25 (3.99) 28.20 (4.01) 0.014 
Creatinine (mmol/l), mean (sd) 97.18 (22.55) 96.56 (21.77) 0.028 
NYHA class III/IV n(%) 205 (24.5) 452 (20.2) 0.104 
Unstable Angina n(%) 73 ( 8.7) 165 ( 7.4) 0.050 
Diabetes n(%)    0.102 
     No history of diabetes 664 (79.4) 1684 (75.2)  
     Insulin dependent diabetes 39 ( 4.7) 132 ( 5.9)  
     Non-insulin dependent diabetes 133 (15.9) 424 (18.9)  
Smoking n(%)    0.085 
     Current smoker 138 (16.5) 304 (13.6)  
     Ex-smoker    462 (55.3) 1259 (56.2)  
     Never smoked 236 (28.2) 677 (30.2)  
COPD/Asthma n(%) 66 ( 7.9) 133 ( 5.9) 0.077 
PVD n(%) 66 ( 7.9) 151 ( 6.7) 0.044 
CVA n(%) 25 ( 3.0) 65 ( 2.9) 0.005 
MI n(%) 369 (44.1) 919 (41.0) 0.063 
PCI n(%) 136 (16.3) 349 (15.6) 0.019 
AF n(%) 15 ( 1.8) 31 ( 1.4) 0.033 
LVEF (\%)    0.047 
      Good (≥50%) 633 (75.7) 1687 (75.3)  
      Moderate (31-49%) 181 (21.7) 508 (22.7)  
      Poor (≤30%) 22 ( 2.6) 45 ( 2.0)  
Antiplatelet regime    0.123 
     None  88 (10.5) 288 (12.9)  
     Aspirin only 506 (60.5) 1412 (63.0)  
    Aspirin plus clopidogrel 207 (24.8) 471 (21.0)  
    Clopidogrel only  35 ( 4.2) 69 ( 3.1)  
Antiplatelet within 3 days n(%) 159 (19.0) 353 (15.8) 0.086 
Warfarin n(%) 17 ( 2.0) 43 ( 1.9) 0.008 
Beta-blockers n(%) 688 (82.3) 1844 (82.3) 0.001 
Statins n(%) 795 (95.1) 2088 (93.2) 0.080 
ACEI/ARB n(%) 526 (62.9) 1531 (68.3) 0.115 
Off-pump surgery n(%) 309 (37.0) 950 (42.4) 0.112 
Use of saphenous vein graft n(%) 676 (80.9) 1699 (75.8) 0.122 
Number of grafts, mean (sd)  3.19 (0.82) 3.18 (0.80) 0.003 
Hospital n(%)    0.61 
     1st Department Of Cardiac Surgery  70 ( 8.4) 74 ( 3.3)  
     2nd Department Of Cardiac Surgery  46 ( 5.5) 209 ( 9.3)  
     Austin Repatriation Medical Centre 176 ( 7.9) 10 ( 1.2)  
     Bydgoszcz Szpital Uniwersytecki  0 ( 0.0) 23 ( 1.0)  
     Care Hospital  0 ( 0.0) 69 ( 3.1)  
     Castle Hill Hospital  61 ( 7.3) 35 ( 1.6)  
     Edinburgh Royal Infirmary  191 (22.8) 22 ( 1.0)  
     Escorts Heart Institute  0 ( 0.0) 19 ( 0.8)  
     Freeman Hospital  0 ( 0.0) 152 ( 6.8)  
     Glenfield Hospital  38 ( 4.5) 56 ( 2.5)  
     Harefield Hospital  36 ( 4.3) 56 ( 2.5)  
     Heart Institute Of Pernambuco  0 ( 0.0) 82 ( 3.7)  
     John Paul Hospital  0 ( 0.0) 92 ( 4.1)  
     John Radcliffe Hospital  102 (12.2) 324 (14.5)  
     King's College Hospital  0 ( 0.0) 114 ( 5.1)  
     Landesklinikum St Polten  17 ( 2.0) 2 ( 0.1)  
     Manchester Royal Infirmary  71 ( 8.5) 44 ( 2.0)  
     Medical University Of Gdansk  3 ( 0.4) 71 ( 3.2)  
     Northern General Hospital  10 ( 1.2) 53 ( 2.4)  
     Ospedale Mauriziano  0 ( 0.0) 61 ( 2.7)  
     Papworth Hospital  2 ( 0.2) 98 ( 4.4)  
     Royal Brompton Hospital  25 ( 3.0) 56 ( 2.5)  
     Royal Sussex County Hospital  51 ( 6.1) 128 ( 5.7)  
     Rzeszow Szpital Wojewodzki 2  2 ( 0.2) 4 ( 0.2)  
     Silesian Centre For Heart Disease  0 ( 0.0) 10 ( 0.4)  
     St. George's Hospital  0 ( 0.0) 77 ( 3.4)  
     The Cardiothoracic Centre  0 ( 0.0) 49 ( 2.2)  
     University Hospital of Wales  101 (12.1) 84 ( 3.8)  
 
SMD: standardized mean difference; BMI: body mass index; NYHA: New York Heart 
Association; COPD: Chronic obstructive pulmonary disease; PVD: peripheral vascular disease; 
CVA: cerebrovascular accident; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; AF: atrial fibrillation; LVEF: left ventricular ejection fraction; ACEI/ARB: 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker 
  
Table S2. Hospital outcomes in the original sample.  
 Aprotinin No Aprotinin 
n  836 2240 
Mortality n(%) 14 ( 1.7) 18 ( 0.8) 
MI n(%) 13 ( 1.6) 41 ( 1.8) 
CVA n(%) 8 ( 1.0) 32 ( 1.4) 
Repeat Revascularization n(%) 8 ( 1.0) 7 ( 0.3) 
POAF n(%) 211 (25.2) 551 (24.6) 
IABP insertion n(%) 52 ( 6.2) 74 ( 3.3) 
RRT n(%) 39 ( 4.7) 122 ( 5.4) 
AKI n(%) 146 (17.5) 396 (17.7) 
Sternal wound infection n(%) 38 ( 4.5) 72 ( 3.2) 
RBC transfusion n(%) 61 ( 7.3) 315 (14.1) 
Re-exploration n(%) 33 ( 3.9) 70 ( 3.1) 
 
MI: myocardial infarction; CVA: cerebrovascular accident; POAF: postoperative atrial 
fibrillation; IABP intra-aortic balloon pump; RRT: renal replacement therapy; AKI: acute kidney 
injury; RBC: red blood cells 
  
Table S3. Five-year outcomes in the original sample.  
 Aprotinin No Aprotinin 
n 836 2240 
Cardiovascular mortality 35(4.2) 71(3.2) 
MI 25(3.0) 79(3.6) 
CVA 21(2.5) 65(2.9) 
Repeat Revascularization  55(6.6) 147(6.7) 
All-cause mortality 82(9.9) 178(8.1) 
 
MI: myocardial infarction; CVA: cerebrovascular accident 
 

